Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.2 per share a year ago.